Fresno, Calif. – August 11, 2021 – Tamarack Biotics, LLC today announced the European Commission approval of TruActive™ products for production and sales throughout the European Union (EU). This approval covers all Ultraviolet treated TruActive™ products, including TruActive™ MPC 85, TruActive™ WPI 90, and TruActive™ LTF, a Lactoferrin product.
“TruActive™ products utilize proprietary UV treatment and low temperature drying processes that retain more of raw milk’s immune active proteins and enzymes than any other product available today,” said Bob Comstock, Chief Executive Officer of Tamarack Biotics. “These immune active proteins offer health benefits to everyone, but particularly young children, sports enthusiasts, and the elderly.”
Tamarack is currently negotiating with potential European production partners and hopes to offer samples by year-end.
A University of California Davis-led clinical trial proved that TruActive™ restored immune function in an elderly population. Raw milk proteins positively impact gut health, and the non-denatured proteins have significantly higher bioavailability. Additionally, the taste, smell, and dissolution are far superior to existing thermally pasteurized products.
Tamarack plans to test TruActive™’s ability to reduce allergy development in children. The European Commission funded Protection against Allergy Study in Rural Environments’ (PASTURE) study demonstrated that children who consume raw milk early in life suffer vastly fewer allergies. Researchers believe bioactive proteins provide this protective effect, and TruActive™ retains these same proteins.